Viridian Therapeutics

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viridian Therapeutics reports strong progress in 2022 with promising trials

Viridian Therapeutics made significant strides in 2022 with positive data on VRDN-001 and plans for Phase 3 trials.
Financially, the company remains strong with $424.6 million in cash, despite increased R&D expenses.
The company's expansion into rare diseases, leadership transition, and strategic clinical site targeting showcase growth potential.
Challenges include dosing frequency impact on efficacy and operational hurdles in patient enrollment and market competition.

Viridian Therapeutics reports strong Q1 performance and strategic advancements

Viridian Therapeutics demonstrated strong performance in clinical trials and financial stability, supported by key hires and strategic partnerships, while facing challenges in investor communication and market access strategies.
The company's focus on innovation in drug delivery methods and pipeline expansion presents opportunities for growth and competitive differentiation in the biopharmaceutical industry.
Overall, Viridian's proactive approach to advancing therapeutic programs and addressing investor concerns positions the company well for future success and potential market impact.

Viridian Therapeutics excels in pipeline progress and financial stability

Viridian Therapeutics showcased strong pipeline progress and financial stability in Q1 2024, with confidence in their transformative therapies.
While facing challenges in regulatory processes and market competition, the company is poised for growth through upcoming program milestones.
Opportunities lie in expanding their therapeutic portfolio, demonstrating product efficacy, and navigating regulatory pathways effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that its President and Chief Executive Officer, Jonathan Violin, Ph.D., will present an overview of the company along with its upcoming corporate priorities at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 2:15 p.m. PST / 5:15 p.m. EST in San Francisco, California.

Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference

Boeing

Caterpillar

Celsius Holdings

Clearfield

Vita Coco

Chevron

DocGo

Enphase Energy

JPMorgan Chase & Co

McDonald's

Merck

Noble Corp PLC

Northern Oil and Gas

Nuvalent

Permian Basin Royalty Trust

Pinduoduo Inc - ADR

Tidewater

TG Therapeutics

Mammoth Energy Services

Visa

Vipshop Hlds

Verizon

Wave Life Sciences

Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining over 10% in less than a week of trading days has reached 235 out of 293 trading weeks (80.4%) not counting multiple gainers.

MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An Edge

- The global THRIVE Phase 3 trial will be conducted in approximately 50 centers across North America and Europe -

Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE' Phase 3 Trial in Patients With Thyroid Eye Disease

Viridian Therapeutics, Inc.'s data in TED beats Tepezza's trial data. Tepezza is a blockbuster drug.

Viridian: Better Data Than A Blockbuster Competitor

Dow Inc

Futu Holdings

Honeywell

Brigham Minerals

NIKE

AiHuiShou International Co Ltd

SPDR S&P 500 ETF Trust

TAL Education Group

Zymeworks Inc

Zynex Inc

Two new Breakout Stocks for Week 50 with better than 10% short-term upside potential and one Dow 30 Pick. Average cumulative returns now up to +131.5% YTD. This week 1 of 4 high frequency breakout picks gained over 10% in less than a week with peak gains in VITL +10.4% while PBT hit +6.22% and CPRX +4.4%.

MDA Breakout Stocks Week 50 - December 2022: Short-Term Picks To Give You An Edge

WALTHAM, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that senior management will participate in the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022.

Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference

G-III Apparel Group

Goldman Sachs

Intel

Lattice Semiconductor

Two new Breakout Stocks for Week 47 with better than 10% short-term upside potential and one Dow 30 Pick. Average cumulative returns now up to +123.7% YTD. This week 2 of 4 picks gained 10%+ in less than a week with FUTU +23.6% and FREY 14.0% of the high frequency breakout movers. VIPS peaked at +9.64%.

MDA Breakout Stocks Week 47 - Short-Term Picks To Give You An Edge

The mean of analysts' price targets for Viridian Therapeutics, Inc. (VRDN) points to an 89.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict an 89% Upside in Viridian Therapeutics, Inc. (VRDN): Here's What You Should Know

Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants John Jordan - Vice President of Investor Relations Jonathan Violin - President & Chief Executive Officer Barrett Katz - Chief Medical Officer Kristian Humer - Chief Financial Officer & Chief Business Officer Conference Call Participants Rami Katkhuda - LifeSci Capital Gavin Clark-Gartner - Evercore ISI Thomas Smith - SVB Securities Laura Chico - Wedbush Securities Kalpit Patel - B. Riley Securities Jason Butler - JMP Securities Operator Greetings and welcome to Viridian Therapeutics Third Quarter 2022 Earnings Call.

Viridian Therapeutics, Inc. (VRDN) Q3 2022 Earnings Call Transcript

- Significant and rapid improvement in both signs and symptoms of TED at week 6 after two infusions of 20 mg/kg VRDN-001; generally consistent with 10mg/kg results at week 6 -

Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 20 mg/kg VRDN-001, generally consistent with 10 mg/kg results at week 6 -

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that management will participate in the Guggenheim 4th Annual Neuro/Immunology Conference on Tuesday, November 15, 2022.

Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th

WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the third quarter ended September 30, 2022, before the financial markets open on Monday, November 14, 2022.

Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022

- Clinical and in vitro data presented in three late-breaking presentations at ATA provide emerging evidence of VRDN-001 efficacy and differentiation -

Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

- Three late-breaking presentations to feature emerging evidence of VRDN-001 efficacy and differentiation -

Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting

Apple

Alector Inc

Invesco Treasury Collateral ETF

Alphabet

G1 Therapeutics

Intrepid Potash

Johnson & Johnson

Microsoft

Direxion Daily Semiconductor Bull 3x Shares

TravelCenters of America

Direxion Daily Utilities Bull 3X Shares

Two new Breakout Stocks for Week 40 with better than 10% short-term upside potential and one Dow 30 pick. Average cumulative returns now up to +105.6% YTD. This week 2 picks beat 10% in less than a week with FUSN +12.2%, LRMR at +12.95% and VYGR +9.2% peak gains continuing in high negative Momentum Gauge warnings.

MDA Breakout Stocks Week 40 - October 2022: Short-Term Picks To Give You An Edge

Amgen

Fusion Pharmaceuticals

Larimar Therapeutics Inc

Two new Breakout Stocks for Week 39 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now down to +108.7% YTD. This week no picks beat 10% gains in less than a week with SLCR peak at +7.1% and continuing the highest negative Momentum Gauges® warning levels since July.

MDA Breakout Stocks Week 39 - September 2022: Short-Term Picks To Give You An Edge

Aerie Pharmaceuticals

Belite Bio Inc

Chemocentryx

Catalyst Pharmaceuticals

Verona Pharma

Akero Therapeutics Inc

Gossamer Bio Inc

Relmada Therapeutics Inc

Ventyx Biosciences

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year appeared first on Investor's Business Daily.

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

Viridian's phase 1/2 data was better than blockbuster competitor drug Tepezza's data. The company is well-funded.

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Viridian Therapeutics hopes to follow Horizon Therapeutics with a best thyroid eye disease drug, and the IPO stock is on a run. The post Why Viridian's CEO Isn't Sweating His Company's Second-Place Position appeared first on Investor's Business Daily.

Why Viridian's CEO Isn't Sweating His Company's Second-Place Position

WALTHAM, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that it has issued an additional 1,725,000 shares of common stock at a public offering price of $23.50 per share, resulting in additional gross proceeds of approximately $40.5 million, pursuant to the exercise in full of the underwriters' option to purchase additional shares of common stock in connection with the Company's previously announced public offering of common stock and Series B Preferred Stock. After giving effect to the full exercise of the underwriters' option to purchase additional shares of common stock, the total number of shares of common stock sold by Viridian in the underwritten public offering was 11,352,640 shares. In addition, approximately 1,872,360 shares of common stock are issuable upon conversion of the 28,084 shares of Series B Preferred Stock sold in the offering. The gross proceeds from the sale of shares of common stock and Series B Preferred Stock were approximately $311 million, before deducting underwriting discounts and commissions and other offering expenses payable by Viridian.

Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters' Option to Purchase Additional Shares in Public Offering

Representing one of the top performers on Monday, shares of Viridian Therapeutics (NASDAQ: VRDN ) skyrocketed as much as 60%. The biotechnology firm released encouraging results for its therapeutic focusing on thyroid eye disease (TED), a rare autoimmune disease.

Viridian Therapeutics (VRDN) Stock Jumps 60% on Promising Clinical Trial

The shares of Viridian Therapeutics Inc (NASDAQ:VRDN) are up 59.5% at $23.50 at last check, despite the company reporting wider-than-expected second-quarter losses of $1.06 per share.

Options Traders Blast Surging Biotech After Earnings

Options Traders Blast Surging Biotech Stock After Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q2 2022 Earnings Conference Call August 15, 2022 8:00 AM ET Company Participants John Jordan - VP of IR Jonathan Violin - President and CEO Barrett Katz - Chief Medical Officer, Raymond Douglas - Director of Thyroid Eye Disease Kristian Humer - CFO and Chief Business Officer Conference Call Participants Chris Howerton - Jefferies Thomas Smith - SVB Securities Gavin Clark-Gartner - Evercore ISI Rami Katkhuda - LifeSci Capital Laura Chico - Wedbush Securities Kalpit Patel - B. Riley Securities FBR Jason Butler - JMP Securities Trevor Allred - Oppenheimer Michael Higgins - Ladenburg Thalmann Operator Greetings, and welcome to the Viridian Therapeutics Conference Call.

Viridian Therapeutics, Inc. (VRDN) CEO Jonathan Violin on Q2 2022 Results - Earnings Call Transcript

News for Viridian Therapeutics Stock (VRDN)